Empowered Patient Podcast

Dr. Travis Mickle President and CEO KemPharm describes the development of AZSTARYS, the stimulant-based methylphenidate prodrug treatment for ADHD one of the most common central nervous system diseases. This prodrug stimulates the norepinephrine dopamine reuptake inhibitor improving concentration, executive function, and irritability and provides for long-acting effect and protection from abuse as it is broken down in the lower GI. Travis' personal experience with ADHD and raising children with ADHD gives him a deep understanding of the challenges facing patients as well as their physicians.

@kempharm #Kempharm $KMPH #ADHD #CNS

KemPharm.com

Listen to the podcast here.

Dr. Travis Mickle President and CEO KemPharm describes the development of AZSTARYS, the stimulant-based methylphenidate prodrug treatment for ADHD one of the most common central nervous system diseases. This prodrug stimulates the norepinephrine dopamine reuptake inhibitor improving concentration, executive function, and irritability and provides for long-acting effect and protection from abuse as it is broken down in the lower GI. Travis' personal experience with ADHD and raising children with ADHD gives him a deep understanding of the challenges facing patients as well as their physicians.

@kempharm #Kempharm $KMPH #ADHD #CNS

KemPharm.com

Download the transcript here.

Dr. Mark Allen, Co-Founder and CEO, Elevian is looking to disrupt the longevity business by developing a recombinant GDF11 to treat and prevent multiple age-related diseases. The first application being investigated is for stroke recovery drawing on the discovery that GDF11 decreases with age and when replenished, returns the brain to a healthier pattern of vascularization. Not looking to extend just the life span, the goal is to target the aging process and extend the healthy lifespan.

@ElevianInc #aging #StrokeRecovery #AgeRelatedDisease #GDF11

Elevian.com

Listen to the podcast here.

Dr. Mark Allen, Co-Founder and CEO, Elevian is looking to disrupt the longevity business by developing a recombinant GDF11 to treat and prevent multiple age-related diseases. The first application being investigated is for stroke recovery drawing on the discovery that GDF11 decreases with age and when replenished, returns the brain to a healthier pattern of vascularization. Not looking to extend just the life span, the goal is to target the aging process and extend the healthy lifespan.

@ElevianInc #aging #StrokeRecovery #AgeRelatedDisease #GDF11

Elevian.com

Download the transcript here.

Dr. Steve Kanes, Chief Medical Officer, Sage Therapeutics takes the view that mental disorders and brain health disorders need to be treated like any other medicine. Driving this paradigm shift is the development of breakthrough zuranalone, an oral limited-time treatment to replace taking medicine chronically for those suffering from major depressive disorder. Clinical trials are showing when people do experience recurrences of MDD and episodes are treated when they occur, there are long and prolonged benefits.

@SageBiotech #depression #MajorDepressiveDisorder #MDD #postpartum

SageRx.com

Listen to the podcast here.

Dr. Steve Kanes, Chief Medical Officer, Sage Therapeutics takes the view that mental disorders and brain health disorders need to be treated like any other medicine. Driving this paradigm shift is the development of breakthrough zuranalone, an oral limited-time treatment to replace taking medicine chronically for those suffering from major depressive disorder. Clinical trials are showing when people do experience recurrences of MDD and episodes are treated when they occur, there are long and prolonged benefits.

@SageBiotech #postpartum #depression #MajorDepressiveDisorder #MDD

SageRx.com

Download the transcript here.

Louis Martinez, Chief Information Officer, EHR Data shines a light on the decentralization of healthcare data collected by providers, insurance carriers, pharmacists and other medical service providers. With a goal of centralizing disparate health data and providing access at point of care, EHR is using blockchain to collect data globally to allow easy access for patients with an ability to grant permission for access to doctors and other health professionals. The pandemic is driving the need to reduce healthcare costs by eliminating redundant efforts and treatments not in the patient's best interest or long-term wellness and for patients to share data to address population health emergencies.

#EHRData #myEHRstory #Wavemaker #COVID19 #blockchain

EHRData.com

Listen to the podcast here

Louis Martinez, Chief Information Officer, EHR Data shines a light on the decentralization of healthcare data collected by providers, insurance carriers, pharmacists and other medical service providers. With a goal of centralizing disparate health data and providing access at point of care, EHR is using blockchain to collect data globally to allow easy access for patients with an ability to grant permission for access to doctors and other health professionals. The pandemic is driving the need to reduce healthcare costs by eliminating redundant efforts and treatments not in the patient's best interest or long-term wellness and for patients to share data to address population health emergencies.

#EHRData #myEHRstory #Wavemaker #COVID19 #blockchain

EHRData.com

Download the transcript here

Vu Truong, CEO, Aridis Pharmaceuticals is taking on the challenge of making an inhaled monoclonal antibody to treat COVID-19 to allow for the easier patient access. Drawing on their work in infectious diseases and with a number of monoclonal antibodies candidates to treat bacteria infection associated with superbugs and antibiotic resistance, Aridis is finding ways to overcome lack of usage of similar potent antibodies from Regeneron and Eli Lilly to combat the coronavirus.

@Aridis_Pharma #AridisPharma #Aridis #Superbugs #AMR #InfectiousDisease #COVID19 #mAb #MonoclonalAntibody #immunotherapy #RespiratoryInfections #CoronavirusVariants

AridisPharma.com

Listen to the podcast here

Vu Truong, CEO, Aridis Pharmaceuticals is taking on the challenge of making an inhaled monoclonal antibody to treat COVID-19 to allow for the easier patient access. Drawing on their work in infectious diseases and with a number of monoclonal antibodies candidates to treat bacteria infection associated with superbugs and antibiotic resistance, Aridis is finding ways to overcome lack of usage of similar potent antibodies from Regeneron and Eli Lilly to combat the coronavirus.

@Aridis_Pharma #AridisPharma #Aridis #Superbugs #AMR #InfectiousDisease #COVID19 #mAb #MonoclonalAntibody #immunotherapy #RespiratoryInfections #CoronavirusVariants

AridisPharma.com

Download the transcript here